Hideyuki Akaza

Q: What Schools Are Affiliated With Hideyuki Akaza

Hideyuki Akaza is affiliated with the following schools: University of Tokyo, University of Tsukuba

Hideyuki Akaza's AcademicInfluence.com Rankings

Hideyuki Akaza

Philosophy

#8887

World Rank

#12351

Historical Rank

Logic

#5899

World Rank

#7348

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Hideyuki Akaza's Degrees

Doctorate Medicine University of Tokyo
PhD Medicine University of Tokyo

Why Is Hideyuki Akaza Influential?

(Suggest an Edit or Addition)

According to Wikipedia, is a Japanese urologist and an author of more than 17 peer-reviewed articles. He graduated from the University of Tokyo and became a professor in urological oncology there. He also served as a professor emeritus at the University of Tsukuba and was a President of both the Asia Pacific Society of Urological Oncology and the 20th Asia Pacific Cancer Conference. From 2005 to 2009 he was a member of both the Japanese Urological Association and the Japan Society of Clinical Oncology in which he started participating in 2006.

(See a Problem?)

Hideyuki Akaza's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Preventive effect of a Lactobacillus casei preparation on the recurrence of superficial bladder cancer in a double-blind trial. The BLP Study Group. (1995) (357)
Nrf2 Is Essential for the Chemopreventive Efficacy of Oltipraz against Urinary Bladder Carcinogenesis (2004) (342)
A review of current guidelines and best practice recommendations for the management of nonmuscle invasive bladder cancer by the International Bladder Cancer Group. (2011) (280)
Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015 (2015) (256)
Comparisons of percent equol producers between prostate cancer patients and controls: case-controlled studies of isoflavones in Japanese, Korean and American residents. (2004) (239)
Prognostic value of cadherin-associated molecules (alpha-, beta-, and gamma-catenins and p120cas) in bladder tumors. (1996) (213)
Noninfectious pneumonitis after everolimus therapy for advanced renal cell carcinoma. (2010) (203)
Antineoplastic activity of honey in an experimental bladder cancer implantation model: In vivo and in vitro studies (2003) (188)
Habitual Intake of Lactic Acid Bacteria and Risk Reduction of Bladder Cancer (2002) (187)
A case‐control study of diet and prostate cancer in Japan: possible protective effect of traditional Japanese diet (2004) (180)
Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer. (2020) (173)
Combined androgen blockade with bicalutamide for advanced prostate cancer (2009) (171)
Nomograms including nuclear matrix protein 22 for prediction of disease recurrence and progression in patients with Ta, T1 or CIS transitional cell carcinoma of the bladder. (2005) (162)
Effects of soybean isoflavones on cell growth and apoptosis of the human prostatic cancer cell line LNCaP. (1998) (159)
Molecular features of hormone-refractory prostate cancer cells by genome-wide gene expression profiles. (2007) (154)
A phase II study of sunitinib in Japanese patients with metastatic renal cell carcinoma: insights into the treatment, efficacy and safety. (2010) (153)
Phase II study to investigate the efficacy, safety, and pharmacokinetics of sorafenib in Japanese patients with advanced renal cell carcinoma. (2007) (150)
Institutional variability in the accuracy of urinary cytology for predicting recurrence of transitional cell carcinoma of the bladder (2006) (140)
Incidence of venous thromboembolism following major abdominal surgery: a multi‐center, prospective epidemiological study in Japan (2006) (139)
Bacillus Calmette–Guerin (BCG) immunotherapy for bladder cancer: Current understanding and perspectives on engineered BCG vaccine (2013) (137)
Clinical evaluation of nuclear matrix protein 22 (NMP22) in urine as a novel marker for urothelial cancer. (1997) (131)
Epidemiology, Staging, Grading, and Risk Stratification of Bladder Cancer (2008) (128)
The impact of real-time tissue elasticity imaging (elastography) on the detection of prostate cancer: clinicopathological analysis (2007) (124)
Tissue elasticity imaging for diagnosis of prostate cancer: A preliminary report (2005) (122)
Risk assessment among prostate cancer patients receiving primary androgen deprivation therapy. (2009) (120)
Real-time elastography for the diagnosis of prostate cancer: evaluation of elastographic moving images. (2009) (116)
Overall survival and updated results from a phase II study of sunitinib in Japanese patients with metastatic renal cell carcinoma. (2010) (116)
Bacillus calmette—Guérin treatment of existing papillary bladder cancer and carcinoma in situ of the bladder. Four‐year results (1995) (113)
Dietary isoflavones may protect against prostate cancer in Japanese men. (2007) (111)
Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. (2019) (110)
Variability in the performance of nuclear matrix protein 22 for the detection of bladder cancer. (2006) (110)
Key predictive factors of axitinib (AG-013736)-induced proteinuria and efficacy: a phase II study in Japanese patients with cytokine-refractory metastatic renal cell Carcinoma. (2011) (109)
Is daidzein non-metabolizer a high risk for prostate cancer? A case-controlled study of serum soybean isoflavone concentration. (2002) (109)
Clinical Practice Recommendations for the Prevention and Management of Intravesical Therapy-Associated Adverse Events. (2008) (108)
Current pathology keys of renal cell carcinoma. (2011) (102)
Orteronel plus prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (ELM-PC 4): a double-blind, multicentre, phase 3, randomised, placebo-controlled trial. (2015) (101)
Phase 3, randomized, placebo‐controlled study of zibotentan (ZD4054) in patients with castration‐resistant prostate cancer metastatic to bone (2012) (99)
Phase I/II clinical trials of carbon ion therapy for prostate cancer (2004) (92)
Phase I study of autologous tumor vaccines transduced with the GM-CSF gene in four patients with stage IV renal cell cancer in Japan: clinical and immunological findings. (2004) (90)
Docetaxel plus prednisolone for the treatment of metastatic hormone-refractory prostate cancer: a multicenter Phase II trial in Japan. (2008) (90)
Effects of a Soybean Isoflavone Mixture on Carcinogenesis in Prostate and Seminal Vesicles of F344 Rats (1999) (89)
Maintenance therapy with bacillus Calmette‐Guérin Connaught strain clearly prolongs recurrence‐free survival following transurethral resection of bladder tumour for non‐muscle‐invasive bladder cancer (2011) (86)
Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. (2019) (85)
Superior anti-tumor efficacy of bicalutamide 80 mg in combination with a luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist monotherapy as first-line treatment for advanced prostate cancer: interim results of a randomized study in Japanese patients. (2004) (85)
Promoting effects and mechanisms of action of androgen in bladder carcinogenesis in male rats. (1997) (83)
Nrf2 and p53 cooperatively protect against BBN-induced urinary bladder carcinogenesis. (2007) (76)
Decreased expression of CXXC4 promotes a malignant phenotype in renal cell carcinoma by activating Wnt signaling (2009) (75)
Clinical evaluation of urothelial tumors of the renal pelvis and ureter based on a new classification system (1987) (75)
Isolation and characterization of the equol-producing bacterium Slackia sp. strain NATTS (2010) (74)
Comparison of various assay systems for prostate-specific antigen standardization. (1992) (74)
A five‐alpha reductase inhibitor or an antiandrogen prevents the progression of microscopic prostate carcinoma to macroscopic carcinoma in rats (1998) (73)
Current status of endocrine therapy for prostate cancer in Japan analysis of primary androgen deprivation therapy on the basis of data collected by J-CaP. (2007) (72)
INTRAVESICAL CHEMOTHERAPY AND IMMUNOTHERAPY: HOW DO WE ASSESS THEIR EFFECTIVENESS AND WHAT ARE THEIR LIMITATIONS AND USES? (1995) (72)
Efficacy of primary hormone therapy for localized or locally advanced prostate cancer: results of a 10‐year follow‐up (2006) (71)
Urinary nuclear matrix protein 22 as a new marker for the screening of urothelial cancer in patients with microscopic hematuria (1999) (69)
Clinical Practice Manual for Late‐onset Hypogonadism Syndrome (2008) (69)
Prostate Cancer Chemoprevention Study: An investigative randomized control study using purified isoflavones in men with rising prostate‐specific antigen (2012) (69)
Efficacy and Safety of Axitinib Versus Sorafenib in Metastatic Renal Cell Carcinoma: Subgroup Analysis of Japanese Patients from the Global Randomized Phase 3 AXIS Trial (2013) (67)
Surface antigen expression on bladder tumor cells induced by bacillus Calmette‐Guérin (BCG): A role of BCG internalization into tumor cells (2002) (65)
Trans‐Pacific variation in outcomes for men treated with primary androgen‐deprivation therapy (ADT) for prostate cancer (2016) (65)
Nanoparticulation of BCG-CWS for application to bladder cancer therapy. (2014) (64)
Prostate Cancer Working Group report. (2010) (63)
Intravesical chemotherapy for maximum prophylaxis of new early phase superficial bladder carcinoma treated by transurethral resection (1999) (59)
Effect of prophylactic treatment with intravesical epirubicin on recurrence of superficial bladder cancer--The 6th Trial of the Japanese Urological Cancer Research Group (JUCRG): a randomized trial of intravesical epirubicin at dose of 20mg/40ml, 30mg/40ml, 40mg/40ml. (2004) (58)
Updated Japanese Urological Association Guidelines on prostate‐specific antigen‐based screening for prostate cancer in 2010 (2010) (58)
Isoflavone supplements stimulated the production of serum equol and decreased the serum dihydrotestosterone levels in healthy male volunteers (2009) (58)
Maintenance intravesical bacillus Calmette‐Guérin instillation for Ta, T1 cancer and carcinoma in situ of the bladder: Randomized controlled trial by the BCG Tokyo Strain Study Group (2010) (57)
Combined androgen blockade for prostate cancer: Review of efficacy, safety and cost‐effectiveness (2011) (56)
Characteristics of patients with prostate cancer who have initially been treated by hormone therapy in Japan: J-CaP surveillance. (2004) (56)
Type 1, P and S fimbriae, and afimbrial adhesin I are not essential for uropathogenic Escherichia coli to adhere to and invade bladder epithelial cells. (2002) (55)
Identification of an Enzyme System for Daidzein-to-Equol Conversion in Slackia sp. Strain NATTS (2011) (54)
Low-grade Ta (noninvasive) urothelial carcinoma of the bladder. (2005) (54)
A bladder preservation regimen using intra‐arterial chemotherapy and radiotherapy for invasive bladder cancer: A prospective study (2000) (50)
Decreased expression of α‐catenin is associated with poor prognosis of patients with localized renal cell carcinoma (1997) (50)
Hamartoma of the urinary bladder (1999) (50)
Influence of isoflavone intake and equol-producing intestinal flora on prostate cancer risk. (2013) (48)
Phase III Trial of Everolimus in Metastatic Renal Cell Carcinoma: Subgroup Analysis of Japanese Patients from RECORD-1 (2010) (48)
Prostate cancer chemoprevention by soy isoflavones: Role of intestinal bacteria as the “second human genome” (2012) (47)
Phase II study ofcis-diammine(glycolato)platinum, 254-S, in patients with advanced germ-cell testicular cancer, prostatic cancer, and transitional-cell carcinoma of the urinary tract (2004) (47)
Management of prostate cancer in Asia: resource-stratified guidelines from the Asian Oncology Summit 2013. (2012) (47)
Efficacy of primary hormonal therapy for patients with localized and locally advanced prostate cancer: A retrospective multicenter study (2006) (46)
Overall survival and good tolerability of long‐term use of sorafenib after cytokine treatment: final results of a phase II trial of sorafenib in Japanese patients with metastatic renal cell carcinoma (2011) (45)
Intraoperative transesophageal echocardiography for inferior vena caval tumor thrombus in renal cell carcinoma (2004) (45)
Clinical study of varicocele: Statistical analysis and the results of long‐term follow‐up (2002) (45)
Antitumor effects of the intravesical instillation of heat killed cells of the Lactobacillus casei strain Shirota on the murine orthotopic bladder tumor MBT-2. (2001) (45)
Lower Urinary Tract Dysfunction as Persistent Complication of Radical Hysterectomy (1997) (44)
Effects of single non-ortho, mono-ortho, and di-ortho chlorinated biphenyls on cell functions and proliferation of the human prostatic carcinoma cell line, LNCaP. (2003) (44)
Age-stratified serum levels of isoflavones and proportion of equol producers in Japanese and Korean healthy men (2008) (44)
Efficacy of dose-intensified MEC (methotrexate, epirubicin and cisplatin) chemotherapy for advanced urothelial carcinoma: a prospective randomized trial comparing MEC and M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin). Japanese Urothelial Cancer Research Group. (1998) (44)
Randomized Controlled Study of the Efficacy, Safety and Quality of Life with Low Dose bacillus Calmette-Guérin Instillation Therapy for Nonmuscle Invasive Bladder Cancer. (2016) (43)
Clinical Practice Recommendations for the Management of Non–Muscle Invasive Bladder Cancer (2008) (42)
Bacillus Calmette-Guérin treatment of existing papillary bladder cancer and carcinoma in situ of the bladder. Four-year results. The Bladder Cancer BCG Study Group. (1995) (41)
Bleomycin-induced pulmonary toxicity in chemotherapy for testicular cancer (2003) (40)
Real-world use of sunitinib in Japanese patients with advanced renal cell carcinoma: efficacy, safety and biomarker analyses in 1689 consecutive patients (2015) (40)
Randomized clinical trial on chemoprophylaxis of recurrence in cases of superficial bladder cancer (2004) (40)
How many uncomplicated male and female overactive bladder patients reveal detrusor overactivity during urodynamic study? (2006) (38)
A NEW TUMOR MARKER FOR BLADDER CANCER (1994) (38)
Recent trends in the initial therapy for newly diagnosed prostate cancer in Japan. (2014) (38)
A phase I study of personalized peptide vaccination using 14 kinds of vaccine in combination with low‐dose estramustine in HLA‐A24‐positive patients with castration‐resistant prostate cancer (2011) (38)
Alterations in Expression of Cadherin–6 and E–Cadherin during Kidney Development and in Renal Cell Carcinoma (2000) (37)
Efficacy and safety of gemcitabine monotherapy in patients with transitional cell carcinoma after Cisplatin-containing therapy: a Japanese experience. (2007) (36)
Bladder cancer develops 6 years earlier in current smokers: Analysis of bladder cancer registry data collected by the cancer registration committee of the Japanese Urological Association (2009) (36)
Bladder cancer induced by noncarcinogenic substances. (1984) (36)
Chemoprevention of rat prostate carcinogenesis by use of finasteride or casodex. (1995) (36)
Bicalutamide 80 mg combined with a luteinizing hormone-releasing hormone agonist (LHRH-A) versus LHRH-A monotherapy in advanced prostate cancer: findings from a phase III randomized, double-blind, multicenter trial in Japanese patients (2007) (36)
Uroepithelial cells can directly respond to Mycobacterium bovis bacillus Calmette‐Guérin through Toll‐like receptor signalling (2006) (35)
Significance of UICC Activities in Global Health Initiatives on Cancer Looking Towards the Future of Cooperative Networks for Cancer Care in Asia - A Dialogue with the Union for International Cancer Control(UICC). (2017) (35)
Future Prospects for Luteinizing Hormone-Releasing Hormone Analogues in Prostate Cancer Treatment (2010) (35)
Goserelin acetate with or without antiandrogen or estrogen in the treatment of patients with advanced prostate cancer: a multicenter, randomized, controlled trial in Japan. Zoladex Study Group. (1999) (35)
Expression of antitumor response role of attachment and viability of bacillus calmette—guérin to bladder cancer cells (1993) (34)
Usefulness of urinary NMP22 to detect tumor recurrence of superficial bladder cancer after transurethral resection (2003) (34)
Trends in primary androgen depletion therapy for patients with localized and locally advanced prostate cancer: Japanese perspective (2006) (34)
The therapeutic effects of R8-liposome-BCG-CWS on BBN-induced rat urinary bladder carcinoma. (2011) (34)
Identification of a type III secretion system in uropathogenic Escherichia coli. (2002) (34)
Proton beam therapy for invasive bladder cancer: a prospective study of bladder-preserving therapy with combined radiotherapy and intra-arterial chemotherapy. (2006) (33)
A case of metastatic testicular cancer complicated by tumour lysis syndrome and choriocarcinoma syndrome. (2006) (33)
A prospective and randomized study of primary hormonal therapy for patients with localized or locally advanced prostate cancer unsuitable for radical prostatectomy: results of the 5‐year follow‐up (2003) (33)
The efficacy and safety of degarelix, a GnRH antagonist: a 12-month, multicentre, randomized, maintenance dose-finding phase II study in Japanese patients with prostate cancer. (2012) (32)
Role of complex cadherins in cell-cell adhesion evaluated by spheroid formation in renal cell carcinoma cell lines. (2004) (32)
Expression of cadherin-6 as a novel diagnostic tool to predict prognosis of patients with E-cadherin-absent renal cell carcinoma. (1998) (32)
FOXO1 and TCF7L2 genes involved in metastasis and poor prognosis in clear cell renal cell carcinoma (2010) (32)
Expression profile of N-cadherin differs from other classical cadherins as a prognostic marker in renal cell carcinoma. (2006) (31)
Higher consumption of green tea may enhance equol production. (2003) (31)
Management of patients with advanced prostate cancer in the Asia Pacific region: ‘real‐world’ consideration of results from the Advanced Prostate Cancer Consensus Conference (APCCC) 2017 (2018) (31)
Phase 3, randomized, placebo-controlled trial of orteronel (TAK-700) plus prednisone in patients (pts) with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC) (ELM-PC 4 trial) (2014) (31)
Intravesical chemotherapy and immunotherapy for superficial tumors Basic mechanism of action and future direction. (1998) (31)
Factors that influence the results of salvage surgery in patients with chemorefractory germ cell carcinomas with elevated tumor markers (2003) (31)
Sustained prophylactic effect of intravesical bacille Calmette-Guérin for superficial bladder cancer: a smoothed hazard analysis in a randomized prospective study. (2006) (30)
Current Approaches to the Management of Non-Muscle Invasive Bladder Cancer : Comparison of Current Guidelines and Recommendations (2008) (30)
A Phase 2 Trial of Abiraterone Acetate in Japanese Men with Metastatic Castration-resistant Prostate Cancer and without Prior Chemotherapy (JPN-201 Study) (2014) (30)
Polymorphisms in estrogen related genes may modify the protective effect of isoflavones against prostate cancer risk in Japanese men (2010) (30)
Negative impact of metabolic syndrome on the responsiveness to sildenafil in Japanese men. (2008) (29)
A low-dose combination therapy of interleukin-2 and interferon-α is effective for lung metastasis of renal cell carcinoma: a multicenter open study (2006) (29)
Comparative analysis of short-term and long-term prophylactic intravesical chemotherapy of superficial bladder cancer (1987) (29)
Transgenic rats carrying copies of the human c-Ha-ras proto-oncogene exhibit enhanced susceptibility to N-butyl-N-(4-hydroxybutyl)nitrosamine bladder carcinogenesis. (2000) (29)
Phase II study of cis-diammine(glycolato)platinum, 254-S, in patients with advanced germ-cell testicular cancer, prostatic cancer, and transitional-cell carcinoma of the urinary tract. 254-S Urological Cancer Study Group. (1992) (29)
Urinary cytology and nuclear matrix protein 22 in the detection of bladder cancer recurrence other than transitional cell carcinoma (2008) (28)
Background Variables for the Patients with Invasive Bladder Cancer Suitable for Bladder-preserving Therapy. (2007) (28)
A case of intravascular papillary endothelial hyperplasia (Masson's tumor) arising from renal sinus. (1997) (28)
Phase II study of the safety and efficacy of temsirolimus in East Asian patients with advanced renal cell carcinoma. (2012) (27)
Tumor–specific autologous cytotoxic T lymphocytes from tissue sections (1996) (27)
Pattern of intravesical recurrence after surgical treatment for urothelial cancer of the upper urinary tract: A single institutional retrospective long‐term follow‐up study (2010) (27)
Evaluation of quality of life in patients with previously untreated advanced prostate cancer receiving maximum androgen blockade therapy or LHRHa monotherapy: a multicenter, randomized, double-blind, comparative study (2008) (26)
A large-scale prospective registration study of the safety and efficacy of sorafenib tosylate in unresectable or metastatic renal cell carcinoma in Japan: results of over 3200 consecutive cases in post-marketing all-patient surveillance (2015) (26)
Progress in prostate cancer chemoprevention: modulators of promotion and progression. (2001) (26)
Overall survival and final efficacy and safety results from a Japanese phase II study of axitinib in cytokine-refractory metastatic renal cell carcinoma (2014) (26)
Long-term results of intravesical chemoprophylaxis of superficial bladder cancer: experience of the Japanese urological cancer research group for Adriamycin (2004) (26)
Prognostic impact of young age on stage IV prostate cancer treated with primary androgen deprivation therapy (2014) (26)
The case for androgen deprivation as primary therapy for early stage disease: results from J-CaP and CaPSURE. (2006) (26)
Detection of cadherin-6 mRNA by nested RT-PCR as a potential marker for circulating cancer cells in renal cell carcinoma. (2003) (25)
Immunoprotection against murine bladder carcinoma by octaarginine‐modified liposomes incorporating cell wall of Mycobacterium bovis bacillus Calmette‐Guérin (2009) (25)
Splenogonadal fusion: Case report and review of published works (2006) (25)
A Phase 2 Study of Abiraterone Acetate in Japanese Men with Metastatic Castration-resistant Prostate Cancer Who Had Received Docetaxel-based Chemotherapy (2014) (24)
Successful outcomes using combination therapy of interleukin-2 and interferon-alpha for renal cell carcinoma patients with lung metastasis. (2010) (24)
New packaging method of mycobacterial cell wall using octaarginine-modified liposomes: enhanced uptake by and immunostimulatory activity of dendritic cells. (2007) (24)
Protecting spermatogonia from apoptosis induced by doxorubicin using the luteinizing hormone‐releasing hormone analog leuprorelin (2003) (24)
Three-weekly docetaxel with prednisone is feasible for Japanese patients with hormone-refractory prostate cancer: a retrospective comparative study with weekly docetaxel alone. (2007) (23)
Chemopreventive effects of cyclooxygenase‐2 inhibitor and epidermal growth factor‐receptor kinase inhibitor on rat urinary bladder carcinogenesis (2006) (23)
Evidence‐based Clinical Practice Guidelines for Prostate Cancer (Summary – JUA 2006 Edition) (2008) (23)
Survival of metastatic germ cell cancer patients assessed by international germ cell consensus classification in Japan. (2008) (23)
[TNM classification]. (1994) (23)
Sorafenib‐associated hand–foot syndrome in Japanese patients (2011) (23)
Prostate cancer trends in Asia (2017) (22)
Progress reports on immune gene therapy for stage IV renal cell cancer using lethally irradiated granulocyte-macrophage colony-stimulating factor-transduced autologous renal cancer cells (2000) (22)
Suppression of AhR signaling pathway is associated with the down-regulation of UDP-glucuronosyltransferases during BBN-induced urinary bladder carcinogenesis in mice. (2010) (22)
Pharmacokinetics of Tamsulosin Hydrochloride in Patients with Renal Impairment: Effects of α1‐Acid Glycoprotein (1996) (22)
Early results of LH-RH agonist treatment with or without chlormadinone acetate for hormone therapy of naive localized or locally advanced prostate cancer: a prospective and randomized study. The Prostate Cancer Study Group. (2000) (22)
Stimulatory effects of growth hormone on rat bladder carcinogenesis (1991) (22)
Serum creatinine level during chemotherapy for testicular cancer as a possible predictor of bleomycin-induced pulmonary toxicity. (1998) (21)
Evidence‐based clinical practice guidelines for bladder cancer (Summary – JUA 2009 Edition) (2010) (21)
Multicenter phase II trial of S-1 in patients with cytokine-refractory metastatic renal cell carcinoma. (2010) (21)
[Ablative and prophylactic effects of BCG Tokyo 172 strain for intravesical treatment in patients with superficial bladder cancer and carcinoma in situ of the bladder. Bladder cancer BCG Study Group]. (1992) (21)
Response criteria phase II/phase III invasive bladder cancer. (1986) (21)
Validation of TNM classification for metastatic prostatic cancer treated using primary androgen deprivation therapy (2016) (21)
[Development of Japanese version of QOL questionnaire for bladder and prostate cancer patients using FACT-Bl and P: pilot study]. (1999) (21)
Treated natural history of superficial bladder cancer. (2001) (21)
Nadir prostate-specific antigen (PSA) level and time to PSA nadir following primary androgen deprivation therapy as independent prognostic factors in a Japanese large-scale prospective cohort study (J-CaP) (2014) (21)
A clinical study of PMCJ-9 (Bacillus Calmette-Guérin Connaught strain) treatment of superficial bladder cancer and carcinoma in situ of the bladder. (2003) (21)
Effect of basic fibroblast growth factor incorporating gelatin microspheres on erectile function in the diabetic rat. (2005) (20)
Gene expression profiles correlate with the morphology and metastasis characteristics of renal cell carcinoma cells. (2005) (20)
Argyrophilic nucleolar organizer region in proliferating cell has a predictive value for local recurrence in superficial bladder tumor. (2000) (20)
Bacillus Calmette-Guerin and BCG cell wall skeleton suppressed viability of bladder cancer cells in vitro. (2010) (20)
Proliferating cell nuclear antigen cyclin in human transitional cell carcinoma. (1995) (20)
Lectin‐reactive alpha‐fetoprotein as a marker for testicular tumor activity (2005) (19)
Bladder reconstruction using a collagen patch prefabricated within the omentum (2006) (19)
BCG treatment of existing Ta, T1 tumours or carcinoma in situ of the bladder. (1995) (19)
Combined androgen blockade achieved better oncological outcome in androgen deprivation therapy for prostate cancer: Analysis of community‐based multi‐institutional database across Japan using propensity score matching (2018) (19)
Metastatic Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy: Treatment Patterns From the PROXIMA Prospective Registry (2018) (18)
A Randomized Phase II Trial of Flutamide vs Chlormadinone Acetate in Previously Untreated Advanced Prostatic Cancer (1993) (18)
Phase I trial of TAK‐385 in hormone treatment‐naïve Japanese patients with nonmetastatic prostate cancer (2019) (18)
Current status and prospects of androgen depletion therapy for prostate cancer. (2008) (18)
Additive effects of antitumor drugs and lymphokine-activated killer cell cytotoxic activity in tumor cell killing determined by lactate-dehydrogenase-release assay (2005) (18)
Effect of Recombinant Human Granulocyte Colony-Stimulating Factor in Patients Receiving Chemotherapy for Urogenital Cancer (1992) (18)
Mechanism responsible for the antitumor effect of BCG-CWS using the LEEL method in a mouse bladder cancer model. (2014) (17)
A case of metastatic testicular cancer complicated by pulmonary hemorrhage due to choriocarcinoma syndrome (2010) (17)
Successful management by provocative angiography and endovascular stent of Ureteroarterial fistula in a patient with a long-term indwelling ureteral stent. (2010) (17)
Key predictive factors for efficacy of axitinib in first-line metastatic renal cell carcinoma: subgroup analysis in Japanese patients from a randomized, double-blind phase II study (2016) (17)
The liposome‐incorporating cell wall skeleton of Mycobacterium bovis bacillus Calmette‐Guéin can directly enhance the susceptibility of cancer cells to lymphokine‐activated killer cells through up‐regulation of natural‐killer group 2, member D ligands (2011) (16)
The level of cadherin‐6 mRNA in peripheral blood is associated with the site of metastasis and with the subsequent occurrence of metastases in renal cell carcinoma (2004) (16)
Neutropenic colitis during standard dose combination chemotherapy with nedaplatin and irinotecan for testicular cancer. (2006) (16)
Injection of Glutaraldehyde Cross‐Linked Collagen for Urinary Incontinence: Two‐Year Efficacy by Self‐Assessment (1996) (16)
NCCN Asia Consensus Statement prostate cancer. (2018) (16)
Axitinib for the treatment of advanced renal cell carcinoma (2014) (16)
YM116, 2-(1H-imidazol-4-ylmethyl)-9H-carbazole, decreases adrenal androgen synthesis by inhibiting C17-20 lyase activity in NCI-H295 human adrenocortical carcinoma cells. (1999) (16)
[Influence of Lactobacillus casei on rat bladder carcinogenesis]. (1994) (16)
Analysis of Intravesical Recurrence After Bladder-preserving Therapy for Muscle-invasive Bladder Cancer. (2012) (16)
Effectiveness and adverse effects of hormonal therapy for prostate cancer: Japanese experience and perspective. (2012) (15)
Early results of radical prostatectomy and adjuvant endocrine therapy for prostate cancer with or without preoperative androgen deprivation (1999) (15)
Current status of chemotherapy in risk‐adapted management for metastatic testicular germ cell cancer (2010) (15)
Comparative investigation on use of (2''R)-4'-O-tetrahydropyranyl-adriamycin and adriamycin as intravesical chemotherapy for superficial bladder tumors. (1988) (15)
Endocrine therapy with or without radical prostatectomy for T1b‐T3N0M0 prostate cancer (2004) (15)
Weight gain and family history of prostate or breast cancers as risk factors for prostate cancer: results of a case-control study in Japan. (2011) (15)
Japan Cancer of the Prostate Risk Assessment for combined androgen blockade including bicalutamide: Clinical application and validation (2013) (15)
Adverse reactions related to treatment compliance during BCG maintenance therapy for non-muscle-invasive bladder cancer. (2013) (14)
Preliminary results of bladder-preserving therapy with definitive radiotherapy and intraarterial infusion of chemotherapy. (1994) (14)
The limited efficacy of methotrexate, actinomycin D and cisplatin (MAP) for patients with advanced testicular cancer. (2003) (14)
Correlation of Allelic Loss of the P53 Gene and Tumor Grade, Stage, and Malignant Progression in Bladder Cancer (1997) (14)
Relationship of serum levels and dietary intake of isoflavone, and the novel bacterium Slackia sp. strain NATTS with the risk of prostate cancer: a case–control study among Japanese men (2016) (14)
Decreased expression of alpha-catenin is associated with poor prognosis of patients with localized renal cell carcinoma. (1998) (14)
Efficacy and safety of leuprorelin acetate 6-month depot in prostate cancer patients: a Phase III, randomized, open-label, parallel-group, comparative study in Japan (2015) (14)
Diagnostic work-up. (1986) (14)
Laminin expression patterns in human ureteral tissue. (2003) (14)
Long-term clinical study on Luteinising hormone-releasing hormone agonist depot formulation in the treatment of stage D prostatic cancer (1992) (14)
Phase-1 study of abiraterone acetate in chemotherapy-naïve Japanese patients with castration-resistant prostate cancer (2014) (14)
Selective cytotoxicity of drug-monoclonal antibody conjugates against murine bladder tumor cells. (1987) (14)
A prognostic significance of nucleolar organizer region (AgNOR) in renal cell carcinoma. (1995) (14)
HPC2/ELAC2 polymorphism associated with Japanese sporadic prostate cancer (2004) (14)
[Evaluation of urinary NMP22 (nuclear matrix protein 22) as a diagnostic marker for urothelial cancer--screening for urothelial cancer in patients with microscopic hematuria. NMP Study Group]. (1997) (14)
Preoperative Endocrine Therapy for Clinical Stage A2, B, and C Prostate Cancer: An Interim Report on Short‐Term Effects (1997) (14)
Randomized controlled study of natural interferon α as adjuvant treatment for stage II or III renal cell carcinoma (2013) (13)
Efficacy and safety of 3‐month dosing regimen of degarelix in Japanese subjects with prostate cancer: A phase III study (2018) (13)
Efficacy and safety of sorafenib for advanced renal cell carcinoma: real-world data of patients with renal impairment (2018) (13)
Global update on defining and treating high‐risk localized prostate cancer with leuprorelin: an Asian perspective (2007) (13)
Paclitaxel, ifosfamide and cisplatin regimen is feasible for Japanese patients with advanced germ cell cancer. (2003) (13)
Leuprorelin Acetate Depot: Results of a Multicentre Japanese Trial (1990) (13)
Long-Term Results of Donor-Specific Blood Transfusion with Cyclosporine in Living Related Kidney Transplantation (2001) (13)
Advanced renal cell carcinoma treated with granulocyte‐macrophage colony‐stimulating factor gene therapy: A clinical course of the first Japanese experience (2002) (13)
Combined immunotherapy with low-dose IL-2 plus IFN-alpha for metastatic renal cell carcinoma: survival benefit for selected patients with lung metastasis and serum sodium level. (2011) (13)
Fifth Joint Meeting of J-CaP and CaPSURE: advancing the global understanding of prostate cancer and its management. (2012) (13)
Detection and Cloning of a Protein Recognized by Anti‐human Prostate‐specific Antigen (PSA) Antibody in the Rat Ventral Prostate (2001) (13)
Clinical evaluation of two consecutive UroVysion fluorescence in situ hybridization tests to detect intravesical recurrence of bladder cancer: a prospective blinded comparative study in Japan (2018) (13)
Reiter’s syndrome following intravesical bacille biliÉ de Calmette–GuÉrin treatment for superficial bladder carcinoma: report of six cases (2004) (13)
Urologic cancer in Japan: role of Japan at the frontier of issues in Asia. (2016) (13)
Weekly administration of docetaxel in patients with hormone-refractory prostate cancer: a pilot study on Japanese patients. (2004) (13)
Expression of ras p21 oncogene product on human bladder tumors. (1989) (12)
The 4th study of prophylactic intravesical chemotherapy with Adriamycin in the treatment of superficial bladder cancer: the experience of the Japanese urological cancer research group of Adriamycin (2004) (12)
New strategy of bio-chemoprevention on recurrence of superficial bladder cancer based on a hypothesis of the mechanism of recurrence. (1997) (12)
The importance of dose intensity in chemotherapy of advanced testicular cancer. (1995) (12)
Completion and toxicity of induction chemotherapy for metastatic testicular cancer: an updated evaluation of Japanese patients. (2006) (12)
Clinical course and immune response of a renal cell carcinoma patient to adoptive transfer of autologous cytotoxic T lymphocytes (2003) (12)
Long‐term results of first‐line sequential high‐dose carboplatin, etoposide and ifosfamide chemotherapy with peripheral blood stem cell support for patients with advanced testicular germ cell tumor (2007) (11)
LH‐RH Agonist, Zoladex (Goserelin), Depot Formulation in the Treatment of Prostatic Cancer Randomized Dose‐Finding Trial in Japan (1988) (11)
Adjuvant goserelin improves clinical disease‐free survival and reduces disease‐related mortality in patients with locally advanced or localized prostate cancer (2004) (11)
The cost of antiemetic therapy for chemotherapy-induced nausea and vomiting in patients receiving platinum-containing regimens in daily practice in Japan: a retrospective study (2012) (11)
Asian trends in primary androgen depletion therapy on prostate cancer (2013) (11)
Risk for intravesical recurrence of bladder cancer stratified by the results on two consecutive UroVysion fluorescence in situ hybridization tests: a prospective follow-up study in Japan (2020) (11)
Counts of Slackia sp. strain NATTS in intestinal flora are correlated to serum concentrations of equol both in prostate cancer cases and controls in Japanese men. (2014) (11)
A phase III, randomized study of the investigational agent TAK-700 plus prednisone for patients with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC). (2011) (11)
Multidisciplinary management of metastatic renal cell carcinoma in the era of targeted therapies. (2012) (11)
Differential profiling analysis of proteins involved in anti-proliferative effect of interferon-alpha on renal cell carcinoma cell lines by protein biochip technology. (2006) (11)
Prolonged treatment with three-weekly docetaxel plus daily prednisolone for metastatic castration-resistant prostate cancer: a multicenter, phase II, open-label, non-comparative, extension study in Japan (2013) (10)
Does tumor size or microvascular invasion affect prognosis in patients with renal cell carcinoma? (2007) (10)
Union for International Cancer Control International Session: Healthcare Economics: The significance of the UN summit non‐communicable diseases political declaration in Asia (2013) (10)
[Clinical phase I and phase II study on a sustained release formulation of leuprorelin acetate (TAP-144-SR), an LH-RH agonist, in patients with prostatic carcinoma. Collaborative++ Studies on Prostatic Carcinoma by the Study Group for TAP-144-SR]. (1990) (10)
Efficacy and safety of dutasteride on prostate cancer risk reduction in Asian men: the results from the REDUCE study. (2011) (10)
Surface markers of lymphocytes infiltrating seminoma tissue. (1980) (10)
Evaluation of efficacy and safety of sorafenib in kidney cancer patients aged 75 years and older: a propensity score-matched analysis (2018) (10)
Pheochromocytoma with remission following phentolamine-induced shock. (1984) (10)
[Bilateral uretero-common iliac arterial fistula with long term uretelal stent: a case report]. (2006) (10)
Sixth joint meeting of J-CaP and CaPSURE--a multinational perspective on prostate cancer management and patient outcomes. (2013) (10)
Effect of recombinant human granulocyte colony stimulating factor (lenograstim) on chemotherapy induced neutropenia in patients with urothelial cancer (1999) (10)
Association of HER‐2 polymorphism with Japanese sporadic prostate cancer susceptibility (2005) (9)
The 5th Conference on Asian Trends in Prostate Cancer Hormone Therapy. (2007) (9)
Report of the Second Asian Prostate Cancer (A-CaP) Study Meeting (2017) (9)
What is the Asian Consensus Statement on NCCN clinical practice guidelines in oncology (NCCN-ACS)? (2016) (9)
Induction of potent antitumour natural‐killer cells from peripheral blood of patients with advanced prostate cancer (2003) (9)
Erratum: Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015 (Annals of Oncology (2015) 26(8) (1589–1604), (S0923753419318691), (10.1093/annonc/mdv257)) (2019) (9)
Validation of the prognostic grouping of the seventh edition of the tumor‐nodes‐metastasis classification using a large‐scale prospective cohort study database of prostate cancer treated with primary androgen deprivation therapy (2013) (9)
Radical prostatectomy and adjuvant endocrine therapy for prostate cancer with or without preoperative androgen deprivation: Five‐year results (2004) (9)
Neutropenic colitis as a complication of high-dose chemotherapy for refractory testicular cancer. (1998) (9)
The Therapeutic Effects of R 8-Liposome-BCG-CWS on BBN-Induced Rat Urinary Bladder Carcinoma (2011) (9)
Diabetes, hypertension, and manic episodes (1996) (9)
Prospective study of combined treatment with interferon‐alpha and active vitamin D3 for Japanese patients with metastatic renal cell carcinoma (2008) (9)
[A case of transitional cell carcinoma of the urinary bladder with high serum level of CEA and CA19-9]. (2001) (9)
Clinical outcomes and nadir prostate-specific antigen (PSA) according to initial PSA levels in primary androgen deprivation therapy for metastatic prostate cancer (2016) (9)
High‐dose chemotherapy with peripheral blood stem cell transplantation for advanced testicular cancer (2000) (9)
Mutual neoplastic promotion by instillation of mitomycin C and cauterization on rat bladder urothelium (1986) (9)
The Influence of handling censored data on estimating progression-free survival in cancer clinical trials (JCOG9913-A). (2002) (8)
A multicenter phase I/II study of enzalutamide in Japanese patients with castration-resistant prostate cancer (2016) (8)
Telomerase Is Upregulated in Irreversible Preneoplastic Lesions during Bladder Carcinogenesis in Rats (2002) (8)
Prophylactic chemotherapy with intravesical instillation of Adriamycin and oral administration of 5-fluorouracil after surgery for superficial bladder cancer (2004) (8)
[Assessment of QOL and survival for patients undergoing radical cystectomy or bladder preservation for invasive bladder cancer]. (1999) (8)
[Evaluation of urinary NMP22 (nuclear matrix protein 22) as a diagnostic marker for urothelial cancer--NMP22 as a urinary marker for surveillance of bladder cancer. NMP22 Study Group]. (1997) (8)
A prospective, randomized controlled study on the treatment of stage C and stage D prostatic cancer with estracyt in combination with other chemotherapeutic agents. (1988) (8)
Efficacy and safety of a 3-month dosing regimen of degarelix in Japanese patients with prostate cancer: a phase II maintenance-dose-finding study (2017) (8)
Tissue-engineered Artificial Urothelium (2000) (8)
Treatment outcome of metastatic testicular cancer at a single institution in Japan, a country with low incidence of germ cell tumor. (2006) (8)
Screening for prostate cancer using prostate-specific antigen alone as a first-line checkup parameter: results of the health checkup system. (2000) (8)
Chemoimmunotherapy of implanted murine bladder cancer. (1983) (8)
Hormonal therapy for prostate cancer: Current topics and future perspectives (2010) (8)
Cavernous hemangioma mimicking a cystic renal cell carcinoma (2008) (8)
Asia prostate cancer study (A-CaP Study) launch symposium (2016) (8)
[Assessment of the quality of life of prostate cancer patients]. (1993) (8)
Background factors and short-term health-related quality of life in patients who initially underwent radical prostatectomy or androgen deprivation therapy for localized prostate cancer in a Japanese prospective observational study (J-CaP Innovative Study-1) (2017) (8)
Prospective randomized trial of natural interferon-alpha versus natural interferon-alpha plus cimetidine in advanced renal cell carcinoma with pulmonary metastasis (2006) (8)
Primary signet ring cell carcinoma of the bladder effectively treated with intra-arterial chemotherapy and radiation therapy: A case report (1995) (8)
An early phase II trial of S-1 in Japanese patients with cytokine-refractory metastatic renal cell carcinoma (2010) (7)
[Histopathological comparison of stage A prostatic adenocarcinoma in Japan and the United States]. (1993) (7)
Extremely acute exacerbation of interstitial pneumonia after interferon-alpha treatment for metastatic renal cell carcinoma (2009) (7)
[Globalization of clinical trials]. (2003) (7)
[Clinical evaluation of flutamide, a pure antiandrogen, in prostatic cancer phase II dose-finding study]. (1993) (7)
Report of the third Asian Prostate Cancer study meeting (2018) (7)
[Clinical early phase II study of bicalutamide (Casodex) in patients with prostatic cancer]. (1996) (7)
Evaluation of Nucleolar Organizer Regions in Human Bladder Cancers by Light- and Electron-Microscopic Morphometry (1998) (7)
Cationized liposomal keto-mycolic acids isolated from Mycobacterium bovis bacillus Calmette-Guérin induce antitumor immunity in a syngeneic murine bladder cancer model (2019) (7)
What should we do to raise awareness on the issue of cancer in the global health agenda? (2010) (7)
Enhancement of T cell proliferative response against autologous cancer cells of a metasatic renal cell carcinoma patient after unexplained regression (2004) (7)
Effect of recombinant granulocyte colony-stimulating factor (rG-CSF) on chemotherapy-induced neutropenia in patients with urogenital cancer (2004) (7)
[Intravesical instillation of doxorubicin or epirubicin for chemoprophylaxis of superficial bladder cancer--the fifth study of the Japanese Urological Cancer Research Group for Adriamycin/Farumorubicin]. (2002) (7)
APAF‐1 is related to an undifferentiated state in the testicular germ cell tumor pathway (2011) (7)
Identification of a set of genes associated with response to interleukin-2 and interferon-α combination therapy for renal cell carcinoma through genome-wide gene expression profiling. (2010) (6)
Effects of combination therapy with a luteinizing hormone-releasing hormone agonist and chlormadinone acetate on rat prostate weight and plasma testosterone levels (2003) (6)
Case of α‐fetoprotein‐producing transitional cell carcinoma of the renal pelvis (2004) (6)
[Analyses of the effects of intravesical Bacillus Calmette-Guerin (Tokyo 172 strain) therapy of superficial bladder cancer]. (1989) (6)
High Rate of Induction of Human Autologous Cytotoxic T Lymphocytes against Renal Carcinoma Cells Cultured with an Interleukin Cocktail (1998) (6)
Roundtable discussion at the UICC World Cancer Congress: looking toward the realization of universal health coverage for cancer in Asia. (2015) (6)
[Histopathological comparison of prostatic adenocarcinoma in Japan and the United States]. (1993) (6)
Persistence of prostatic intraepithelial neoplasia after effective chemoprevention of microscopic prostate cancer with antiandrogen in a rat model. (2006) (6)
[Randomized cross-over study on the effects of methylprednisolone, metoclopramide and droperidol on the control of nausea and vomiting associated with cis-platinum chemotherapy]. (1986) (6)
Renal oncocytoma mimicking hemorrhagic renal cyst. (1995) (6)
Circulating immune complexes in patients with bladder cancer and other malignancies of the urogenital tract. (1984) (6)
Recent trend of androgen deprivation therapy in newly diagnosed prostate cancer patients: Comparing between high‐ and middle‐income Asian countries (2021) (6)
Clinical parameters that predict histology of postchemotherapy retroperitoneal lymph node mass in testicular cancer (2004) (6)
Promoting effects of antiandrogenic agents on rat ventral prostate carcinogenesis induced by 3,2′-dimethyl-4-aminobiphenyl (DMAB) (2000) (6)
Epidemiological Survey of Sexually Transmitted Diseases Prevalence in Japan : Sentinel Surveillance of STDs in 2000 (2001) (6)
Long-term survival of extremely advanced prostate cancer patients diagnosed with prostate-specific antigen over 500 ng/ml. (2014) (6)
[Clinical utility of the free prostate specific antigen (PSA), alpha 1-antichymotrypsin-complexed PSA, and free/total PSA ratio using the specific and sensitive enzyme-linked immunosorbent assay "E-plate EIKEN PSA"]. (1998) (6)
Serum creatinine and cholesterol levels of testicular cancer patients in long‐term follow up (2005) (6)
Family history in primary hormone therapy for prostate cancer: Analysis from a community‐based multi‐institutional Japan‐wide database (2020) (6)
Evaluation of the effectiveness of sildenafil using questionnaire methods versus audio‐visual sexual stimulation (2005) (6)
Blood isoflavone levels during intake of a controlled hospital diet. (2004) (6)
[Phase I trial of 4'-O-tetrahydropyranyl-doxorubicin (THP)--a multi-institutional cooperative study]. (1985) (6)
Phase II trial of carboplatin in patients with advanced germ-cell testicular tumors and transitional cell carcinomas of the urinary tract (2004) (6)
847: Institutional Variability in Predictive Accuracy of Urinary Cytology for Prediction of Transitional Cell Carcinoma Recurrence (2005) (6)
Asian trends in prostate cancer hormone therapy. (2002) (6)
[Cerebellar metastasis from renal cell carcinoma]. (1986) (6)
Evaluation of primary androgen deprivation therapy in prostate cancer patients using the J-CAPRA risk score (2013) (6)
[A way of thinking of a MAB therapy for local/locally advanced prostate cancer: the theory and recent evaluation]. (2007) (6)
Advanced prostate cancer treatment guidelines: a global perspective; trends of hormone therapy in Japan (2004) (6)
Enzalutamide + androgen deprivation therapy (ADT) versus flutamide + ADT in Japanese men with castration‐resistant prostate cancer: AFTERCAB study (2021) (5)
Long-term clinical study on luteinising hormone-releasing hormone agonist depot formulation in the treatment of stage D prostatic cancer. The TAP-144-SR Study Group. (1992) (5)
[Significance of tumor markers in the treatment of urological malignancies]. (1987) (5)
Comparative analysis of shortterm and long-term prophylactic intravesicla chemotherapy of superficial bladder cancer. (1987) (5)
[Clinical study of RU 23908 (nilutamide) in prostatic cancer]. (1991) (5)
[Clinical effects of a 3-month formulation LH-RH agonist (Zoladex LA 10.8 mg depot) in patients with prostate cancer]. (2001) (5)
AgNOR Count in Resting Cells (Resting NOR) Is a New Prognostic Marker in Invasive Bladder Tumor (2001) (5)
A new molecular targeted therapeutic approach for renal cell carcinoma with a p16 functional peptide using a novel transporter system. (2011) (5)
Objective response criteria in phase II and phase III studies. (1988) (5)
Global update on defining and treating high‐risk localized prostate cancer with leuprorelin: a Japanese perspective – the effect of primary androgen deprivation therapy on stage C prostate cancer (2007) (5)
[Platinum compounds in cancer therapy--past, present, and future]. (2001) (5)
Triple urogenital cancer in a patient with a history of heavy smoking who had been exposed to the Hiroshima atomic bomb explosion. (1988) (5)
雄性ラットのN-butyl-N-(4-hydroxybutyl) nitrosamine 膀胱発癌に及ぼす Luteinizing hormone-releasing hormone agonist の影響 (1992) (5)
Long-term outcomes of combined androgen blockade therapy in stage IV prostate cancer (2015) (5)
[Urological cancer]. (2009) (5)
[Cases of refractory testicular cancer treated with all trans-retinoic acid]. (1999) (5)
Increase of T lymphocytes bearing immunoglobulin G receptors during circulation in human renal cell carcinoma. (1982) (5)
The 2nd conference on Asian trends in prostate cancer hormone therapy. (2003) (5)
[Neoadjuvant chemotherapy in muscle-invasive bladder cancer]. (2007) (4)
Effectiveness of Maximal Androgen Blockade (MAB): illusion or reality? (2005) (4)
Seventh Joint Meeting of K-J-CaP and CaPSURE: extending the global initiative to improve prostate cancer management (2014) (4)
[A randomized long-term comparative study of clinical efficacy of alpha 1-blocker with or without antiandrogen therapy for benign prostatic hyperplasia: focusing on improvement of I-PSS]. (2000) (4)
[Clinical phase III study on TAP-144-SR, an LH-RH agonist depot formulation, in patients with prostatic cancer]. (1991) (4)
[Assessment of reproducibility and unidimensionality of International Prostate Symptom Score Japanese version]. (1997) (4)
Axitinib in metastatic renal cell carcinoma: beyond the second-line setting. (2017) (4)
[Cooperative phase II study of epirubicin (EPI) in bladder cancer, renal pelvic and ureteral tumors--Urological Cooperative Study Group of EPI]. (1986) (4)
Should patients with localized prostate cancer receive primary androgen deprivation therapy? (2008) (4)
Prophylactic Intravesical Chemotherapy: Its Unexpected Course (1982) (4)
Regional difference in cancer detection rate in prostate cancer screening by a local municipality in Japan (2014) (4)
Clinical benefits of long-term use of sorafenib in Japanese patients with unresectable renal cell carcinoma (RCC) (2008) (4)
[Effects of luteinizing hormone-releasing hormone agonist on bladder carcinogenesis in male rats]. (1992) (4)
Antiemetic efficacy of granisetron: a randomized crossover study in patients receiving cisplatin-containing intraarterial chemotherapy. (1999) (4)
The 3rd Conference on Asian Trends in Prostate Cancer Hormone Therapy. (2004) (4)
[New combination chemotherapy in urological cancers]. (2000) (4)
[Assessment of quality of life as an endpoint of cancer treatment]. (2000) (4)
Prediction of in vitro response to interferon‐α in renal cell carcinoma cell lines (2007) (4)
Crescentic glomerulonephritis associated with renal cell carcinoma after cancer immunotherapy. (2005) (4)
Aim of the working group on the Asian perspectives on cancer control: Asian perspective on prostate cancer prevention. (2010) (4)
Subsets of T lymphocytes of patients with malignancies of the urogenital tract. (1979) (4)
Lower urinary tract function after intra-arterial chemotherapy with concurrent pelvic radiotherapy for invasive bladder cancer. (1999) (4)
Re: Per-Uno Malmström, Richard J. Sylvester, David E. Crawford, et al. An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer. Eur Urol 2009;56:247-56. (2010) (4)
Treatment of prostatic cancer with TAP-144-SR, a depot preparation of LH-RH agonist (leuprolide). (1989) (4)
859 UNCONTROLLED CONFIRMATORY TRIAL OF SINGLE-AGENT SORAFENIB IN JAPANESE PATIENTS WITH ADVANCED RENAL CELL CARCINOMA (2007) (4)
Hormones, growth factors and benign prostatic hyperplasia (BPH) (1991) (4)
A phase 1 multiple-dose study of orteronel in Japanese patients with castration-resistant prostate cancer (2014) (4)
Little Impact on Renal Function in Advanced Renal Cell Carcinoma Patients Treated with Sorafenib--Analyses of Postmarketing Surveillance in Japan in over 3,200 Consecutive Cases. (2016) (4)
Evaluation of systemic chemotherapy with methotrexate, vinblastine, Adriamycin, and cisplatin for advanced bladder cancer (2004) (4)
[Phase I study of bicalutamide (Casodex), a nonsteroidal antiandrogen in patients with prostatic cancer]. (1996) (4)
Non Muscle Invasive Bladder Cancer Cases Initially Failing to Respond to Bacillus Calmette-Guérin Intravesical Instillation Therapy (2010) (4)
Ex vivo gene therapy using granulocyte-macrophage colony-stimulating factor-transduced tumor vaccines. (2000) (4)
[Transabdominal ultrasonography for detection of urologic diseases in the general health check]. (1994) (4)
Regional and facility disparities in androgen deprivation therapy for prostate cancer from a multi‐institutional Japan‐wide database (2021) (4)
[The physical, mental and social impacts of telling prostate cancer patients the true diagnosis]. (1997) (3)
Retroperitoneal extragonadal germ cell tumor in a patient with Klinefelter's syndrome (2005) (3)
[Endocrine therapy of prostatic carcinoma with slow release (depot) formulation of the LH-RH analog ICI 118630 (Zoladex)]. (1988) (3)
Experience with androgen deprivation therapy for prostate cancer in Japan and future perspectives. (2015) (3)
Immunological protection induced by bacillus Calmette–Guérin treatment in a murine bladder tumor model (2002) (3)
A phase II study of S-1 for the treatment of cytokine-refractory metastatic renal cell carcinoma. (2009) (3)
A phase II study of the efficacy and safety of sunitinib in treatment-naive and pretreated Japanese patients (pts) with metastatic renal cell carcinoma (mRCC) (2008) (3)
Long‐term outcomes of androgen deprivation therapy in prostate cancer among Japanese men over 80 years old (2021) (3)
[Promotive effects of intravesical instillation of dimethylsulfoxide on bladder carcinogenesis in mice]. (1992) (3)
[Bropirimine (U-54461S) late phase II clinical study for carcinoma in situ of the bladder. Japan Bropirimine Study Group]. (1997) (3)
Addition of bicalutamide 80 mg to LHRH-agonist monotherapy in patients with advanced prostate cancer: Impact on quality of life. (2004) (3)
Diagnosis of Non-Muscle Invasive Bladder Cancer (2008) (3)
Diminished helper-T-lymphocyte function in cancer patients. (1982) (3)
The eighth Asia cancer forum: seeking to advance the outcomes of the UN summit: 'global health as the key to a new paradigm in cancer research'. (2012) (3)
Acute Thrombosis in a Contralateral Kidney after Radical Nephrectomy: Successful Treatment by Thrombolytic Therapy Using a Tissue‐Type Plasminogen Activator (1996) (3)
[Post launch studies]. (2002) (3)
Unusual presentation of necrotizing fasciitis in a patient who had achieved long‐term remission after irradiation for testicular cancer (2005) (3)
724 TRANS-PACIFIC VARIATION IN OUTCOMES FOR MEN TREATED WITH PRIMARY ANDROGEN DEPRIVATION THERAPY FOR LOCALIZED PROSTATE CANCER (2013) (3)
Report of the forth Asian Prostate Cancer (A-CaP) study meeting. (2019) (3)
Challenges and outlook for the UICC-Asian Regional Office. (2013) (3)
[Serum pancreatic enzyme elevation under treatment with sorafenib]. (2012) (3)
前立腺癌患者の身体・精神・社会面に対する病名告知の影響 (1997) (3)
Testicular cancers occurring in brothers with cryptorchism (2002) (3)
Clinical evaluation of urethral tumors based on a simple classification system. (1988) (3)
[Response criteria for prostatic cancer treated by chemotherapy or antiandrogenic therapy]. (1987) (3)
Real-world use of temsirolimus in Japanese patients with unresectable or metastatic renal cell carcinoma: recent consideration based on the results of a post-marketing, all-case surveillance study (2020) (3)
The effect of dose intensity on M-VAC therapy for advanced urothelial cancer (2004) (3)
Prostate cancer control--aims of the UICC Asia Regional Office Consortium. (2006) (3)
Trans-Pacific variation in outcomes for men treated with primary androgen deprivation therapy for localized prostate cancer. (2013) (3)
Efficacy of S-1 in Patients with Castration-Resistant Prostate Cancer: A Phase II Study (2010) (3)
Real-world use of sorafenib for advanced renal cell carcinoma patients with cardiovascular disease: nationwide survey in Japan (2020) (3)
HERO phase III trial: Results comparing relugolix, an oral GnRH receptor antagonist, versus leuprolide acetate for advanced prostate cancer. (2020) (3)
[The role of mechanical stimuli in rat bladder carcinogenesis. Regenerative hyperplasia of rat urinary bladder urothelium after transurethral fulguration]. (1984) (3)
Developing therapies for advanced bladder cancer (2002) (3)
Assessment of the number of local cytotoxic T lymphocytes required for degradation of micrometer-size tumor spheroids (2001) (3)
[Phase I study of flutamide, a nonsteroidal antiandrogen, in patients with prostatic cancer]. (1993) (3)
Strategy for Prevention of Recurrence of Superficial Bladder Cancer (1996) (2)
[Phase II collaborative study of (2''R)-4'-0-tetrahydropyranyladriamycin (THP) for urological malignancies--Urological Co-operative THP Study Group]. (1986) (2)
RT-PCR double assays of CA9 and/or cadherin-6 in renal cell carcinoma patients. (2004) (2)
[A phase II pharmacological study of leuprolide acetate 6-month depot, TAP-144-SR (6M), in treatment-Nazve patients with prostatic cancer who received a single subcutaneous or intramuscular injection]. (2014) (2)
[Clinical effects of a 3-month formulation LH-RH agonist, TAP-144-SR (3M) in prostate cancer patients]. (2002) (2)
INTRALUMINAL ULTRASONOGRAPHY IN UROLOGY; DEVELOPMENT OF ENDOSCOPIC ULTRASONOGRAPHY USING FLEXIBLE MINIATURE PROBE (1999) (2)
Case of alpha-fetoprotein-producing transitional cell carcinoma of the renal pelvis. (2004) (2)
[Comparative studies on the antitumor activity of fluorinated pyrimidine derivatives against human bladder, cervical and ovarian cancer xenografts in nude mice]. (1991) (2)
Japanese Cancer Association Meeting UICC International session--what is cost-effectiveness in cancer treatment? (2014) (2)
[Renal cell carcinoma with bilateral adrenal and small intestinal metastases: a case report]. (2006) (2)
767: NRF2 is Essential for the Chemopreventive Efficacy of Oltipraz Against Urinary Bladder Carcinogenesis (2005) (2)
[Chemotherapy and radiotherapy for urological cancer]. (2002) (2)
Restoration of E-rosette formation by bestatin in patients with bladder cancer (2004) (2)
Acute multifocal bacterial nephritis complicated with acute renal failure and thrombocytopenia. (2005) (2)
7147 Efficacy and safety of long-term use of sorafenib: final report of a phase II trial of sorafenib in Japanese patients with unresectable/metastatic renal cell carcinoma (2009) (2)
[Effects of LH-RH analogue on pituitary-testicular axis and bladder carcinogenesis of BBN administered male rats]. (1989) (2)
[Collaborative study of UFT in far-advanced renal cell carcinoma. Urological Cooperative UFT Study Group]. (1988) (2)
Advances in chemotherapy of invasive bladder cancer (2000) (2)
UICC-ARO Symposium at the UICC 2016 World Cancer Congress How Can We Mobilize Action to Realize UHC in Asia? (2017) (2)
[Comparison of management of advanced cancer in various organs]. (2001) (2)
A systematic review and meta-analysis on the safety and efficacy of different strains of Mycobacterium bovis bacillus Calmette-Guérin for non-muscle invasive bladder cancer in Japan and US (2015) (2)
Principle Component Analysis of Health-Related Quality of Life Measures for Prostate Cancer (2016) (2)
[Development of molecular targeting drugs for the treatment of cancer-therapeutic potential and issues to be addressed in global development]. (2000) (2)
792PTREATMENT PATTERNS IN PATIENTS (PTS) WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) PREVIOUSLY TREATED WITH DOCETAXEL (DOC)-BASED CHEMOTHERAPY (CTX): PROXIMA. (2014) (2)
Prediction of in vitro response to interferon-alpha in renal cell carcinoma cell lines. (2007) (2)
Bicalutamide 80 mg in combination with an LHRHa versus LHRHa monotherapy in previously untreated advanced prostate cancer: a double-blind, placebo-controlled trial (2005) (2)
[A new anti-androgen, bicalutamide (Casodex), for the treatment of prostate cancer--basic clinical aspects]. (1999) (2)
Extended analyses: Combined androgen blockade (CAB) therapy with bicalutamide vs. luteinizing hormone-releasing hormone agonist (LHRHa) monotherapy in Japanese men with untreated advanced prostate cancer (2008) (2)
A randomized controlled trial evaluating the effect of low-dose chlormadinone in patients with low-risk prostate cancer: PROSAS study (2021) (2)
Post-marketing observational study of everolimus in patients with unresectable or metastatic renal cell carcinoma in Japan. (2019) (2)
[A case of urinary ascites probably caused by spontaneous bladder rupture]. (1995) (2)
[The relationship between the estimated tumor growth speed and indices of bromodeoxyuridine (BrdU) incorporation and the proliferating cell nuclear antigen (PCNA) expression in superficial bladder cancer]. (1997) (2)
[Treatment of testicular and second cancer]. (1999) (2)
[A case report of an ectopic ureter in a patient treated for chronic prostatitis]. (1993) (2)
Bropirimine, an Orally Active Anticancer Agent for Superficial Bladder Cancer (1998) (2)
[Intra-arterial cisplatin and concurrent radiation for invasive bladder cancer]. (1991) (2)
Dynamics of conditional survival and risk factors in androgen deprivation therapy for prostate cancer using a multi‐institutional Japan‐wide database (2021) (2)
Special Edition EAU-ICUD - Review - Kidney Cancer Current Pathology Keys of Renal Cell Carcinoma (2011) (2)
New treatment approaches for superficial and invasive bladder cancer. (1998) (2)
[Verify the optimum administration of anticancer agent--cisplatin]. (2001) (2)
[Clinical application of extracorporeal shock wave lithotripter]. (1985) (2)
Intraluminal ultrasonography in urology. (1998) (2)
[New era of the treatment of CRPC in Japan]. (2014) (2)
Modified J‐CAPRA scoring system in predicting treatment outcomes of metastatic prostate cancer patients undergoing androgen deprivation therapy (2020) (2)
[The significance of lymphocytic infiltration in urologic tumors: studies of distributions of B and T-lymphocytes and its subsets, and functional analysis of the infiltrating lymphocytes (author's transl)]. (1981) (2)
Symposium: “Oncology Leadership in Asia” (2017) (2)
[Fibroepithelial polyp of the prostatic urethra: report of two cases and review of the literature]. (1994) (2)
[Comparison of clinical effects between granisetron alone and combination of granisetron and methylprednisolone against the nausea and vomiting induced by CDDP chemotherapy--comparative study by the cross-over trial. University of Tsukuba Antiemetics Study Group]. (1996) (2)
Phase III trial of The Japanese Urological Cancer Research Group for Adriamycin: cyclophosphamide, adriamycin and cisplatinum versus cyclophosphamide, adriamycin and 5-fluorouracil in patients with advanced transitional cell carcinoma of the urinary bladder (2004) (2)
[The critical appraisal of QOL questionnaire for prostate cancer patients]. (1999) (2)
[Significance of current bio- and molecular-markers in urological cancers]. (2004) (2)
[Effects of androgen regulation system on bladder carcinogenesis in male mice]. (1995) (2)
[Cost-effectiveness analysis of maximum androgen blockade for Japanese men with advanced prostate cancer]. (2007) (2)
[Trends in patterns of care for prostatic cancer in Japan: statistics of 9 institutions for 5 years]. (1988) (2)
[Clinical efficacy of long-term treatment with LH-RH analogue, ICI 118630 (Zoladex), in prostatic cancer patients. The Zoladex Multicenter Study Group]. (1988) (2)
Effect of recombinant human granulocyte colony-stimulating factor in patients receiving methotrexate/vinblastine/doxorubicin/cisplatin therapy for the treatment of transitional cell carcinoma of the urinary tract. (1994) (2)
Cross-boundary Cancer Studies at the University of Tokyo: View from the world of science and reason. (2014) (2)
Effect of recombinant human granulocyte colony-stimulating factor in patients receiving chemotherapy for urogenital cancer. Urological rhG-CSF Study Group. (1992) (2)
Inverted papilloma: Observation with scanning and transmission electron microscopy (2004) (2)
[Treatment of renal cell carcinoma with human lymphoblastoid interferon alpha and UFT in combination. A prospective multicenter trial]. (1991) (2)
[Combined effects of interferon-alpha and 5-fluorouracil, or cis-diamminedichloroplatinum (II) on murine bladder tumor in vivo]. (1986) (2)
[Future prospects for primary hormone therapy in localized and locally advanced prostate cancer]. (2003) (2)
[Combination therapy with natural type human tumor necrosis factor (MHR-24) and human lymphoblastoid interferon-alpha (MOR-22) against renal cell carcinoma--a multiclinic cooperative, early phase II study. Subcommittee on Urogenital Malignancy, Committee on MHR-24 against Tumors]. (1992) (2)
[Meta-analysis and evidence based medicine]. (2002) (2)
Prospective randomized trial of natural interferon-alpha (IFN) versus IFN + cimetidine in advanced renal cell carcinoma with pulmonary metastasis. (2004) (2)
Impact of concomitant prostate cancer therapy on efficacy and safety of relugolix versus leuprolide in men with advanced prostate cancer: Subgroup analysis from the phase III HERO study. (2021) (2)
Chlormadinone acetate withdrawal syndrome under combined androgen blockade for advanced prostate cancer. (1995) (2)
Efficacy of flutamide-combined androgen blockade therapy in advanced prostate cancer patients: a phase III randomized, comparative trial. (2014) (2)
[Intrascrotal tumors: a clinicopathologic study of 15 cases]. (2000) (1)
[Long-term survival with experience of normal delivery after ureterosigmoidostomy. A case report (author's transl)]. (1978) (1)
Final results of a phase II study of S-1 in patients with cytokine-refractory metastatic renal cell carcinoma. (2014) (1)
[An overview of clinical trials in endocrine therapy for cancer]. (1996) (1)
Early androgen suppression may reduce disease progression and improve long term survival compared with deferred androgen suppression in locally advanced prostate cancer. (2003) (1)
[Superficial bladder cancer: prophylaxis of recurrence and progression]. (1991) (1)
Decreased Expression of a-Catenin is Associated With Poor Prognosis of Patients With Local- (1955) (1)
Bellini duct carcinoma accompanied by hemorrhagic renal cyst: A case report and review of the literature (1995) (1)
[Cancer screening]. (2005) (1)
Report from the second Japanese Urological Association–Japanese Society of Medical Oncology joint conference, 2007: ‘Diagnosis and treatment of urological malignant tumors: How can we promote subspecialists?’ (2008) (1)
[Safety and efficacy of docetaxel in prostate cancer patients: based on the post-marketing surveillance in Japan]. (2012) (1)
Low expression of microphthalmia‐associated transcription factor, a potential molecular target for interferon‐alpha susceptibility, is associated with metastasis in renal cell carcinoma (2009) (1)
[A study of the relation between clinical prognostic factors and the estimated tumor growth speed in superficial bladder cancer]. (1996) (1)
Precision medicine, Universal Health Coverage (UHC) and intestinal microflora as a new platform for health promotion (2019) (1)
[Hydrostatic pressure treatment for the bladder cancer (The 3rd report) (author's transl)]. (1976) (1)
Bladder cancer: Advancing NMIBC treatment beyond current BCG formulations (2016) (1)
[Effect of UFT on treatment of urological cancer--effect of UFT on treatment of invasive bladder cancer and advanced prostate cancer. Ibaraki Urological Cancer Chemotherapy Study Group]. (1998) (1)
[A case of synchronous multifocal urothelial tumors in a patient with phenacetin abuse]. (1999) (1)
[A case of Kallmann syndrome: usefulness of the aging male's symptoms rating scale for assessment of subjective symptoms]. (2006) (1)
Prostate cancer in multi‐ethnic Asian men: Real‐world experience in the Malaysia Prostate Cancer (M‐CaP) Study (2021) (1)
[A Multi-Stakeholder Dialogue on Universal Health Coverage for Cancer in Asia - Seeking an Approach to Asia Health and Wellbeing Initiative]. (2018) (1)
Transurethral resection of benign prostatic hyperplasia using a vaporizing resecting loop, UROloop. (1999) (1)
Cross-boundary cancer studies at the University of Tokyo: Surviving cancer in Asia: introduction. (2014) (1)
262: Nomograms for Bladder Cancer Recurrence According to Grade and Stage (2004) (1)
Interim safety results from the all cases post-marketing study (PMS) of sunitinib in 1,027 Japanese patients with renal cell carcinoma (RCC) or gastrointestinal stromal tumor (GIST). (2011) (1)
[Characteristics of screening-detected prostate cancer on health checkup]. (1998) (1)
The 7th Asia Cancer Forum: from the perspective of human security, how can we collaborate as Asians in order to place cancer on the global health agenda? How can we fill in the gaps that exist among us? (2011) (1)
Phase I/II study of S-1 in combination with sorafenib for metastatic renal cell carcinoma. (2015) (1)
[Clinical statistical studies of bladder cancer in Japan]. (1993) (1)
Objective response criteria in prostate cancer. (1990) (1)
Renal cell carcinoma with bilateral adrenaland the small intestinal metastases: A case report (2006) (1)
Age at diagnosis on prostate cancer survival undergoing androgen deprivation therapy as primary treatment in daily practice: results from Japanese observational cohort (2014) (1)
[NCCN Asian consensus statement - can Asian patients with cancer accept treatment modalities from NCCN guidelines ?]. (2014) (1)
[The significance of assessment of quality of life as a cancer treatment]. (2002) (1)
Species differences in regenerative hyperplasia of bladder urothelium after transurethral cauterization (2004) (1)
[Guideline for proper use of antineoplastic agents. Urologic cancer]. (2002) (1)
[Histological and flow cytometric analyses of carcinogenesis of rat prostate cancer]. (1990) (1)
Combined androgen blockade may have long term survival benefits over monotherapy, but may increase adverse effects and reduce quality of life in advanced prostate cancer. (2003) (1)
Multicenter study of the BCG Tokyo strain for intravesical treatment in patients with superficial bladder cancer. BCG Study Group. (1989) (1)
Reduced membrane receptor activity of polymorphonuclear leucocytes of cancer patients. (1980) (1)
[Recent advance in luteinizing hormone-releasing hormone analogue therapy in management of prostate cancer]. (1998) (1)
Proven Efficacy of Combined Androgen Depletion Therapy (2010) (1)
[Effects of UFT in advanced renal cell cancer]. (1985) (1)
Epidemiology and prevention. (1993) (1)
[Current status and future direction of the treatment of CRPC (castration resistant prostate cancer)]. (2014) (1)
[Treatment of tumors of the urinary bladder (author's transl)]. (1978) (1)
The 6th Asia cancer forum: what should we do to place cancer on the global health agenda? Sharing information leads to human security. (2011) (1)
[Nondestructive synchrotron radiation X-ray fluorescence imaging of trace elements in renal cell carcinoma]. (1994) (1)
Impact of age on efficacy and safety of relugolix: A subgroup analysis from the randomized, phase 3 hero study versus leuprolide in men with advanced prostate cancer. (2021) (1)
Report from the 1st Japanese Urological Association‐Japanese Society of Medical Oncology joint conference, 2006: ‘A step towards better collaboration between urologists and medical oncologists’ (2007) (1)
[Prostate cancer]. (1999) (1)
[Usefulness and positioning of MAB therapy for prostate cancer]. (2005) (1)
Efficacy and safety of sequential use of everolimus in Japanese patients with advanced renal cell carcinoma after failure of first-line treatment with vascular endothelial growth factor receptor tyrosine kinase inhibitor: a multicenter phase II clinical trial (2017) (1)
The efficacy and safety of degarelix, a GnRH receptor antagonist: A multicenter, randomized, maintenance dose-finding phase II study with Japanese prostate cancer patients. (2011) (1)
Gene-modified immunotherapy for renal cell carcinoma. (1999) (1)
Influences of the Results from STRIVE Trial on the Combination Androgen Depletion Therapy for Advanced Prostate Cancer (2016) (1)
A randomized phase II trial of flutamide vs chlormadinone acetate in previously untreated advanced prostatic cancer. The Japan Flutamide Study Group. (1993) (1)
[A randomized trial of PVB, VAB-6, BVP regimen versus PEB chemotherapy in patients with disseminated testicular tumors]. (1991) (1)
Efficacy and safety of sunitinib (SU) in patients (pts) with metastatic renal cell carcinoma (mRCC) and lung metastases (mets) only at baseline. (2012) (1)
[Experimental intravesical treatment of bladder tumor with Concanavalin-A conjugated bleomycin]. (1984) (1)
Serum Isoflavone Concentrations and Equol-Producing Intestinal Flora inProstate Cancer in Japanese-American in Hawaii (2016) (1)
[High-dose chemotherapy with peripheral blood stem cell autotransplantation for patients with poor-risk testicular germ cell tumors--pilot study of the Japan Blood Cell Transplantation Study Group]. (1999) (1)
Isoflavones in Japanese and Caucasian men with prostate cancer in Hawaii. (2014) (1)
Hormonal therapy for localized prostate cancer in Japan: The outcome of J-CaP database. (2012) (1)
[The evaluation of chemotherapy of relapse in prostatic cancer with new response criteria]. (1987) (1)
[Retroperitoneal liposarcoma with intrarenal metastases which was difficult to distinguish from angiomyolipoma. A case report]. (1993) (1)
Enzyme activity and protein content of superoxide dismutase isozymes in human renal cell carcinoma. (2000) (1)
THE 4TH STUDY OF PROPHYLACTIC INTRAVESICAL CHEMOTHERAPY USING ADRIAMYCIN FOR THE TREATMENT OF SUPERFICIAL BLADDER CANCER : EXPERIENCE OF THE JAPANESE UROLOGICAL CANCER RESEARCH GROUP INVESTIGATING ADRIAMYCIN (1997) (1)
Efficacy of CAB therapy in stage C prostate cancer: Exploratory analyses based on results of a double-blind, randomized, placebo-controlled phase III study of bicalutamide (2007) (1)
[Endocrine therapy for prostatic carcinoma--the clinical trial to compare the efficacy of LH-RH analogue, ICI 118630 (Zoladex) with castration or estrogen]. (1988) (1)
[Results of clinical study with epirubicin hydrochloride injectable solution for superficial bladder cancer. IMI28 Injectable Solution Study Group for Superficial Bladder Cancer]. (1998) (1)
[Late phase II clinical study for bropirimine (U-54461S) in situ carcinoma of the bladder: follow-up investigation. Bropirimine Study Group]. (1999) (1)
UICC International Session: What are the implications of sharing the concept of Universal Health Coverage for cancer in Asia? (2016) (1)
Phase I trial of personalized peptide vaccine for HLA-A24 positive patients with advanced cancer (2008) (0)
DECREASE IN PROLIFERATION AND INCREASE IN DIFFERENTIATION IS ACCOMPANIED WITH LOW APAF-1 PROTEIN EXPRESSION IN TESTICULAR GERM CELL TUMOR PATHWAY (2009) (0)
[Molecule based diagnosis]. (2004) (0)
Detection of Early-Stage Renal Dysfunction in the Patients with Lower Urinary Tract-Passage Obstruction (1996) (0)
955 POOR PROGNOSIS AFTER PRIMARY ANDROGEN DEPRIVATION THERAPY IN STAGE IV PROSTATE CANCER PATIENTS LESS THAN 55 YEARS OLD (2013) (0)
POS-03.87: Significance of magnetic resonance image prior to prostate biopsies for the consideration of unnecessary biopsies (2007) (0)
[Early detection and prevention of cancers in various therapeutic areas. Discussion]. (1999) (0)
[Clinical study on the effect of CSF-HU (colony stimulating factor human urine) on leukopenia and granulocytopenia induced by cancer chemotherapy--a double-blind study in patients with genito-urinary cancer]. (1988) (0)
Urologic Malignancies: Introduction (2000) (0)
Joint Symposium of Korean Cancer Association & UICC-ARO-Cross-boundary cancer studies: cancer and Universal Health Coverage (UHC) in Asia. (2017) (0)
[Cancer prevention]. (2005) (0)
UP-02.227 A Possibility of Prostate Cancer Chemoprevention by Diet (2011) (0)
[Four cases of bladder replacement by enterocystoplasty after radical cystectomy for bladder cancer]. (1990) (0)
432: The Genetic Polymorphisms of HPC/ELAC2 and HER-2 Gene Associate with Japanese Sporadic Prostate Cancer (2004) (0)
659: Efficacy of Primary Hormone Therapy for Localized and Locally Advanced Prostate Cancer: Results of 10-Year Follow-Up (2006) (0)
[Evidence-based medicine for urological cancer chemotherapy]. (2000) (0)
Background variables for the patients with invasive bladder cancer suitable for bladder-preserving therapy (2007) (0)
Fourth Joint Meeting of the American Urological Association and the Japanese Urological Association Specialty Society Program at the 104th Annual Meeting of the American Urological Association at Chicago 2009 (2009) (0)
A phase I study of S-1 in combination with sorafenib in metastatic renal cell carcinoma (mRCC). (2012) (0)
[Clinical effect of long-term administration of PSK in a combination in patients with malignant urologic cancer]. (1982) (0)
218: Uniparental Polysomy of Chromosome 3Q is a Potential Metastatic Marker in the Patient with Clear Cell Renal Cell Carcinoma (2007) (0)
[Clinical study of the advanced testicular tumor non-achieved complete response by primary chemotherapy and relapse cases. The East Japan Testicular Tumor Study Group]. (1994) (0)
[Urological Cancer Recent Trend of Clinical Studies of Urological Cancer]. (2021) (0)
Neurogenic lower urinary tract dysfunctions after spinal vascular diseases: urodynamic findings and lower urinary tract management (2010) (0)
FORKHEAD TRANSCRIPTION FACTOR FOXO1 IS INVOLVED IN PROGRESSION OF RENAL CELL CARCINOMA (2009) (0)
[Detection of platinum concentration in mice on administrated cisplatin--compared total reflection X-ray fluorescence spectrometry (TRXRF) with atomic absorption spectrometry (AAS)]. (1996) (0)
S&T-20 VALIDATION OF TNM CLASSIFICATION FOR METASTATIC PROSTATIC CANCER TREATED USING PRIMARY ANDROGEN DEPRIVATION THERAPY (2016) (0)
[Recent advancement of the treatment of urological malignancies]. (1999) (0)
S14:Introduction(Symposium 14「Management of Superficial Bladder Cancer」) (2006) (0)
Poster Sessions (2002) (0)
What Contribution Can Pharmaceutical Companies Make to Cancer in Asia? Cross-boundary Cancer Studies at the University of Tokyo: Oncology in Asian Countries: Clinical Development Challenges and Opportunities (2014) (0)
Current Asia Pacific anticancer therapy and research initiatives and strategies. (2010) (0)
[Hypospadia syndrome]. (1993) (0)
[Recent advancement in diagnosis and treatment of prostate cancer--general concepts]. (2005) (0)
Curriculum in Urology Renal Failure and Andrology (1998) (0)
[Bronchial arterial infusion therapy for lung metastases of urogenital tumors]. (1996) (0)
Contents Vol. 68, 2002 (2002) (0)
[Urethral occurrence of bladder cancer following cystectomy]. (1983) (0)
[Adult Wilms's tumor with histologically dissisimilar lung metastasis]. (1994) (0)
[Histological effects of endocrine therapy on prostatic cancer]. (1990) (0)
Renal function in advanced renal cell carcinoma patients treated with sorafenib: Subset analyses of post-marketing surveillance in Japan with over 3,200 consecutive cases. (2016) (0)
[The antiemetic effect, safety and usefulness of tropisetron capsule in the treatment of nausea and vomiting induced by lower multiple dose of cisplatin]. (1995) (0)
[Urological Cancer Genito-Urinary Cancer-Message from Heisei to Reiwa]. (2020) (0)
Sunitinib (SU) pharmacokinetic (PK)-pharmacodynamic (PD) modeling with respect to safety and efficacy endpoints in Asian patients (pts) with gastrointestinal stromal tumor (GIST) or renal cell carcinoma (RCC) in pursuit of a therapeutic window. (2011) (0)
[Cancer chemotherapy in the future. Discussion]. (2003) (0)
Title Sixth joint meeting of J-Cap and CaPSURE-A multinational perspective on prostate cancer management and patient outcomes Permalink (2013) (0)
1795: Tissue Elasticity Imaging for Prostate Diagnosis (2004) (0)
[Four Questions about Prostate Cancer in Japan]. (2017) (0)
EXPRESSION OF CADHERIN-6 MRNA IS POOR PROGNOSTIC FACTOR FOR PATIENTS WITH T1-T3 RENAL CELL CARCINOMA (2009) (0)
What is diagnosed by elastography (2005) (0)
Review article Intravesical chemotherapy and immunotherapy for superficial tumors: Basic mechanism of action and future direction (1999) (0)
622P Geographical assessment of efficacy and safety of relugolix: A subgroup analysis from the randomized, phase III HERO study vs leuprolide (LEU) in men with advanced prostate cancer (APC) (2021) (0)
[Prostate cancer]. (2001) (0)
621P Efficacy and safety of relugolix vs leuprolide (LEU) in men with advanced prostate cancer (APC): Clinical subgroup analysis from the phase III HERO study (2021) (0)
[Why is prostate cancer important in clinical field, now?]. (1996) (0)
[Benign and malignant renal tumors]. (1997) (0)
[Antitumor effect of combined use of purified human natural tumor necrosis factor (N-TNF) and cis-diamminedichoroplatinum (II) (cisplatin) on the implanted bladder carcinoma (MBT-2) in mice]. (1992) (0)
[High-dose chemotherapy with autologous bone marrow transplantation or peripheral blood stem cell transplantation--testicular cancer]. (1995) (0)
A phase II study of S-1 in patients with hormone-refractory prostate cancer: The S-1 Cooperative Study Group (Prostate Cancer) study. (2006) (0)
Analysis of tolerability of intravesical bacillus Calmette-Guérin (BCG) therapy in non-muscle-invasive bladder cancer. (2012) (0)
A phase I study of S-1 in combination with sorafenib in metastatic renal cell carcinoma (mRCC). (2012) (0)
[The transition and future prospective of the study about prostate cancer]. (2016) (0)
[Genitourinary tumor]. (2014) (0)
[Long-acting depot of LH-RH agonist]. (2000) (0)
Subject Index Vol. 68, 2002 (2002) (0)
[Phenotypic difference of lymphocytes circulating in tumorous renal artery and renal vein in patients with renal cell carcinoma]. (1993) (0)
[Reevaluation of MAB therapy and progress of endocrine therapy]. (2005) (0)
[Management of non-seminomatous germ cell tumors of the testes]. (2000) (0)
[Hydrostatic pressure treatment for malignant lesions of the urinary bladder. 4th report. Analysis of the follow-up results (author's transl)]. (1976) (0)
Bladder-preserving therapy for muscle-invasive bladder cancer: Should it be recommended to appropriate patients? (2008) (0)
V1919: Endoscopic Diagnosis of Bladder Carcinoma with Newly Developed "Narrow-Band Imaging" System (2007) (0)
[A case of papillary cystadenoma of the epididymis]. (1998) (0)
[Genitourinary cancer, biomarker; current progress]. (2012) (0)
Abstract 1840: What are the implications for cancer research of placing cancer on the global health agenda (2011) (0)
[Prostate cancer prevention]. (2015) (0)
[Bladder cancer]. (2001) (0)
[Improvement of survival of testicular cancer patients through chemotherapy]. (1995) (0)
254 COMBINED ANDROGEN BLOCKADE IS UNDERUSED IN ADVANCED PROSTATE CANCER: FINDINGS FROM AN INTERNATIONAL SURVEY (2007) (0)
[Renal pelvic tumor (transitional cell carcinoma, squamous cell carcinoma, adenocarcinoma, etc.)]. (1997) (0)
213 LOW EXPRESSION OF MICROPHTHALMIA-ASSOCIATED TRANSCRIPTION FACTOR, POTENTIAL MOLECULAR TARGET FOR INTERFERON-ALPHA SUSCEPTIBILITY, IS PREDICTOR FOR METASTASIS IN RENAL CELL CARCINOMA (2010) (0)
Oncologists' perceptions and treatment practice variations in the treatment of hormone-refractory prostate cancer (HRPC): a pilot multinational study (2001) (0)
Development and analysis of androgen receptor (AR) axis biomarkers of circulating tumor cells (CTCs) in Japanese metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with abiraterone acetate (AA). (2014) (0)
[The 2nd Japan Public-Private Dialogue Forum-A Multi-Stakeholder Dialogue on Universal Health Coverage for Cancer in Asia-Seeking an Approach to Asia Health and Wellbeing Initiative]. (2019) (0)
1325: Maintenance Chemotherapy with Gemcitabine and Paclitaxel for M-VAC Refractory Metastatic Transitional Cell Carcinoma (2005) (0)
Multicenter phase II clinical trial of everolimus in Japanese patients with unresectable or metastatic renal cell carcinoma (mRCC) after failure of treatment with first-line tyrosine kinase inhibitor (TKI) therapy. (2014) (0)
489 ANALYSIS OF NON-INVASIVE BLADDER CANCER WHICH DEVELOPS AFTER BLADDER-PRESERVING THERAPY FOR INVASIVE BLADDER CANCER (2011) (0)
MP-14.08: Diagnostic ureteroscopy for upper urinary tract tumours (2007) (0)
A phase II study of S-1 for the treatment of cytokine and/or tyrosine-kinase inhibitor (TKI) refractory metastatic renal cell carcinoma: Updated results. (2012) (0)
President ’ s Lecture Asian Perspective on Prostate Cancer Prevention (2009) (0)
How Do Cancer Researchers Perceive the Future of Cancer in Asia ? (2014) (0)
[New direction of cancer hormonal therapy--concepts of this issue]. (1996) (0)
[Future directions of anticancer drug development in Japan]. (2008) (0)
767: N-Cadherinis Playing a Roleas a Cell-Cell Adhesion Molecule Under Impairedfunction of E-Cadherin and Cadherin-6 in Renal Cell Carcinoma (2004) (0)
Cost-effectiveness analysis of enzalutamide for patients with chemotherapy-naïve metastatic castration-resistant prostate cancer in Japan (2021) (0)
7165 POSTER Sunitinib (SU) Pharmacokinetic (PK)-Pharmacodynamic (PD) Modeling With Respect to Safety and Efficacy Endpoints in Asian Patients With Gastrointestinal Stromal Tumour (GIST) or Renal Cell Carcinoma (RCC) in Pursuit of a Therapeutic Window (2011) (0)
[The possibility of S-1 for the treatment of patients with urological cancers]. (2006) (0)
[Globalization of anti-cancer therapies]. (2002) (0)
RECENT STATUS AND PROBLEMS OF CANCER THERAPY IN THE FIELD OF UROLOGY (1999) (0)
[Not Available]. (2002) (0)
[Recurrent urological cancer--diagnose and treatment]. (1998) (0)
[The squash technique for silver staining of argyrophilic nucleolar organizer regions on bladder tumors: comparison with paraffin embedded sections]. (1995) (0)
[Clinical observation of carcinoma in situ of the bladder]. (1986) (0)
[Treatment of elderly patients with urological cancer]. (1994) (0)
Subject Index Vol. 54, 1995 (1995) (0)
214 IDENTIFICATION OF CHARACTERISTIC GENE EXPRESSION IN SARCOMATOID RENAL CELL CARCINOMA (2010) (0)
[Multidisciplinary treatment of invasive bladder cancer]. (1986) (0)
The Importance of Dose Intensity in the Chemotherapy of Advanced Testicular Cancer (1994) (0)
[Analysis of site differences in voiding condition of elderly men-- comparison to results of mass screening for prostate diseases between the villages of Shimamaki-mura, Hokkaido and Satomi-Mura, Ibaraki]. (1996) (0)
[Development of new drugs for urological cancers]. (1997) (0)
[Hydrostatic pressure treatment for non-cancerous contracted bladder--1st report (author's transl)]. (1978) (0)
[Current status of the treatment of urothelial tumors]. (1988) (0)
Efficacy and Safety of Gemcitabine Monotherapy in Patients with Transitional Cell Carcinoma after Cisplatin-Containing Therapy: (2007) (0)
URINARY RETENTION IN A FEMALE SUCCESSFULLY MANAGED WITH BIOFEEDBACK THERAPY : A CASE REPORT (1995) (0)
Thanks to authors and peer reviewers (2007) (0)
903PThe efficacy and safety of sorafenib in patients with renal insufficiency of advanced renal cell carcinoma: Real- world data of sorafenib in Japan (2017) (0)
POSTER VIEWING SESSION - STEM CELLS (2011) (0)
Real-world use of sorafenib for advanced renal cell carcinoma patients with cardiovascular disease: Nationwide survey in Japan. (2019) (0)
Prognostic Value of Cadherin-associated Molecules (a-, /3-, and y-Catenins and pl20cfli) in Bladder Tumors (2017) (0)
Isolation of equol-producing bacterium to realize chemoprevention of prostate cancer. (2011) (0)
Recent Trends in Hormone Therapy for Prostate Cancer in Japan (2018) (0)
Prophylactic Effect of a Lactobacillus casei Preparation on the Recurrence of Bladder Cancer (1997) (0)
[Current Clinical Practice Pattern for Castration-Resistant Prostate Cancer(CRPC)in Japan]. (2021) (0)
DECREASED CXXC4 EXPRESSION CORRELATES METASTASIS AND POOR SURVIVAL IN RENAL CELL CARCINOMA (2008) (0)
[Urological Cancer 2015]. (2016) (0)
The efficacy and safety in elderly patients with advanced renal cell carcinoma: Real-world use of sorafenib in Japan. (2017) (0)
[Salvage therapy for refractory testicular cancer]. (1996) (0)
Lecture No. 2 Is UHC for cancer in Asia an achievable goal? (2021) (0)
[Renal cell carcinoma]. (2004) (0)
[Genitourinary Tumor Four Questions about Bladder Cancer]. (2018) (0)
Subject Index Vol. 78, 2010 (2010) (0)
THE SIGNIFICANCE OF LYMPHOCYTIC INFILTRATION IN UROLOGIC TUMORS: STUDIES OF DISTRIBUTIONS OF B AND T-LYMPHO- CYTES AND ITS SUBSETS, AND FUNCTIONAL ANALYSIS OF THE INFILTRATING LYMPHOCYTES (2010) (0)
histologic classification of renal cell carcinoma Clear cell renal cell carcinoma Multilocular clear cell renal cell carcinoma Papillary renal cell carcinoma Chromophobe renal cell carcinoma Carcinoma of the collecting ducts of Bellini Renal medullary carcinoma Xp 11 translocation carcinomas Carcino (2011) (0)
[Preoperative chemotherapy in genitourinary cancer]. (1995) (0)
An asterisk indicates reviewers who have evaluated three or more manuscripts in 2012. (2013) (0)
Fournier's gangrene detected at an early stage: A case report (1994) (0)
[Genitourinary tumor]. (2013) (0)
[alpha-Interferon therapy in a patient with renal cell carcinoma and renal hypofunction]. (1995) (0)
[Prognosis of renal cell carcinoma and detection of numerical chromosome aberration]. (1997) (0)
Dietary Isoﬂavones May Protect against Prostate Cancer in Japanese Men 1,2 (2007) (0)
[The clinical merit of anti-RANKL antibody denosumab in prostate cancer]. (2012) (0)
Program at a Glance (2018) (0)
2549 Treatment patterns in patients (pts) with metastatic castrationresistant prostate cancer (mCRPC) previously treated with docetaxel (DOC)-based chemotherapy (CT): PROXIMA 1-year analysis (2015) (0)
Third Joint Meeting of the American Urological Association and the Japanese Urological Association International Program at the 103rd Annual Meeting of the American Urological Association at Orlando 2008 (2008) (0)
A phase II study of the efficacy and safety of sunitinib in Japanese patients with metastatic renal cell carcinoma (mRCC) (2008) (0)
MP24-07 RELUGOLIX VS LEUPROLIDE EFFECTS ON CASTRATION RESISTANCE-FREE SURVIVAL FROM THE PHASE 3 HERO STUDY IN MEN WITH ADVANCED PROSTATE CANCER (2021) (0)
F. K. Mostofi HISTOPATHOLOGICAL COMPARISON OF PROSTATIC ADENOCARCINOMA IN JAPAN AND THE UNITED STATES (2010) (0)
[Surgery and adjuvant chemotherapy of disseminated testicular cancer]. (1986) (0)
[Hydrostatic pressure treatment for malignant primary lesions of the urinary bladder. 5th Report-serum alpha1-antitrypsin levels versus treatment effects (author's transl)]. (1978) (0)
TRENDS IN PATTERNS OF CARE FOR PROSTATIC CANCER IN JAPAN: STATISTICS OF 9 INSTITUTIONS IN THESE 5 YEARS (2018) (0)
Preparative and Clinical Studies of Immunogene Therapy Using Autologous GM-CSF Transduced Tumor Vaccines for Stage IV Renal Cell Cancer (1999) (0)
IDENTIFICATION OF PRETREATMENT PROGNOSTIC FACTOR FOR PATIENTS WITH INTERMEDIATE- AND POOR-RISK METASTATIC TESTICULAR CANCER (2009) (0)
860 Proton therapy for invasive bladder cancer: Treatment results of a bladder-preserving therapy with x-ray irradiation and concurrent intra-arterial chemotherapy followed by proton irradiation boost (2003) (0)
889: Predictive Accuracy, Sensitivity, and Specificity of Nuclear Matrix Protein 22 and Urine Cytology for Prediction of Recurrence of Non-Transitional Cell Carcinoma of the Bladder (2006) (0)
Intravesical ultrasound tomography with miniature probe for bladder cancer (1993) (0)
Progress and controversies in chemotherapy of advanced unresectable and/or metastatic carcinoma of the bladder. (1988) (0)
638: Uroepithelial Cell Can Directly Respond To Mycobacterium Bovis Bacillus Calmette-Guérin Through Toll-Like Receptors Signaling (2006) (0)
[The role of etoposide therapy in urogenital cancer]. (1996) (0)
[Discriminant analysis of quantification theory on prognostic factors of chemotherapeutic effects on advanced testicular cancer. East Japan Testicular Tumor Study Group]. (1990) (0)
Bladder-sparing regimen using intra-arterial chemotherapy and radiotherapy for invasive bladder cancer (2005) (0)
Contents Vol. 78, 2010 (2010) (0)
[Characteristics, effects, side effects of the LH-RH agonist]. (2002) (0)
1961: MR Imaging of Prostate Cancer: Can Early Phase of the Dynamic Contrast Enhanced MRI Demonstrate Tumor Nodule and its Extension Arising from Anterior Gland or Transition Zone of the Prostate? (2004) (0)
Abstract 4454: Global health as the key to a new paradigm in cancer research (2012) (0)
Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. (2019) (0)
[Young's syndrome]. (1993) (0)
S14-1 Recurrence hazards of superficial bladder cancer after TURBT(Symposium 14「Management of Superficial Bladder Cancer」) (2006) (0)
[Epoch making development of new drugs for prostate cancer]. (2013) (0)
Abstract 1359: Addressing diverse perceptions of cancer in Asia: Lifestyle and awareness study in China as preliminary step towards the creatin of an Asian cancer barometer. (2013) (0)
947: Chemopreventive Effects of COX-2 Inhibitor and Epidermal Growth Factor (EGF)-Receptor Kinase Inhibitor on Rat Urinary Bladder Tumorigenesis (2004) (0)
Emerging perspectives in prostate cancer: Insights from the 4th Asia Pacific Prostate Cancer Conference☆ (2015) (0)
Analysis of time to castration-resistant prostate cancer (CRPC) after initiating primary androgen depletion therapy (PADT) of prostate cancer. (2012) (0)
Family history in primary hormone therapy for prostate cancer from a community-based multi-institutional Japan-wide database. (2019) (0)
[Progress in oral anti-cancer drug therapy for urological cancer]. (1999) (0)
MP-16.14 Improved Grouping System Combining Gleason Score for Group IV of TNM Prognostic Grouping for Prostate Cancer: Results from J-CAP Database (2011) (0)
[Case of a testicular germ cell tumor presenting with multiple metastasized pulmonary nodules and masses]. (2010) (0)
A low-dose combination therapy of IL-2 and IFNα for metastatic renal cell cancer. (2004) (0)
LBA02-07 HERO PHASE 3 TRIAL: RESULTS COMPARING RELUGOLIX, AN ORAL GNRH RECEPTOR ANTAGONIST, VS LEUPROLIDE ACETATE FOR ADVANCED PROSTATE CANCER (2020) (0)
Response criteria in research protocols for prostatic cancer. (1990) (0)
[Urological Cancer Four Questions about Renal Cell Cancer]. (2019) (0)
Title Fifth joint meeting of J-CaP and CaPSURE : Advancing the global understanding of prostate cancer and its management Permalink (2012) (0)
A phase II study of S-1 for the treatment of cytokine and/or tyrosine-kinase inhibitor (TKI) refractory metastatic renal cell carcinoma: Updated results. (2012) (0)
[Treatment of prostatic carcinoma with UFT and leucovorin--basic study using SRCA]. (1994) (0)
Evaluation of efficacy and safety of sorafenib in kidney cancer patients aged 75 years and older: a propensity score-matched analysis (2018) (0)
ACaseofMetastaticTesticularCancerComplicatedbyTumourLysis Syndrome and Choriocarcinoma Syndrome (2006) (0)
Primary Androgen-Depletion Therapy Prevails Not Only for Metastatic but Also for Nonmetastatic Hormone-Naïve Prostate Cancer in Japan-Recent Trends and Efficacy. (2021) (0)
[Genitourinary tumor]. (2015) (0)
[Detection of numerical chromosome aberrations in urologic malignancies using in situ hybridization from formarin-fixed paraffin sections]. (1993) (0)
[Percent free prostate-specific antigen: a marker for detection of prostate cancer]. (1998) (0)
[Experiences of total cystectomy for superficial bladder cancer]. (1984) (0)
[Genitourinary cancer]. (2009) (0)
[Saphenous vein grafting for Peyronie's disease: a case report]. (2002) (0)
RISK ASSESSMENT AMONG PROSTATE CANCER PATIENTS MANAGED WITH PRIMARY ANDROGEN DEPRIVATION THERAPY: A TRANSPACIFIC STUDY (2009) (0)
Real-time tissue elasticity imaging (Elastography) for prostate cancer detection (2005) (0)
Enzalutamide plus androgen deprivation therapy (ADT) versus flutamide plus ADT in men with castration-resistant prostate cancer (CRPC): AFTERCAB. (2021) (0)
Recurrent pheochromocytoma at the contralateral adrenal gland: A case report (1996) (0)
President ’ s Statement Aim of the Working Group on the Asian Perspectives on Cancer Control : Asian Perspective on Prostate Cancer Prevention (2010) (0)
MP70-16 COMPARISON OF OVERALL SURVIVAL BETWEEN THE LIFE EXPECTANCY AND THE ACTUAL ESTIMATED OUTCOME IN PATIENTS WHO RECEIVED PRIMARY ANDROGEN DEPRIVATION THERAPY (2014) (0)
Antitumor effect of cationic liposome incorporating keto-mycolic acid from Mycobacterium bovis bacillus Calmette-Guérin in mouse model. (2018) (0)
[Epidemiology and prevention]. (2016) (0)
TREATMENT OF TUMORS OF THE URINARY BLADDER (2010) (0)
Genitourinary Cancer (1987) (0)
[Subrenal capsule assay of nude mice for testing the effectiveness of UFT for rat prostatic carcinoma (R3327)]. (1993) (0)
[Short- and long-term outcome after urethroplasty in the patients with hypospadias treated by Hodgson III method]. (1999) (0)
Hormonal therapy for localized prostate cancer in Japan: The outcome of J-CaP database. (2012) (0)
[Antiemetic effects of MS-5080 associated with cisplatin chemotherapy--an attempt in assessment based on the sample score system using multivariate analysis]. (1987) (0)
[Five-year trend in new patients with prostatic carcinoma]. (1988) (0)
P Prostate Cancer Chemoprevention Study : An investigative randomized control study using purified isoflavones in men with rising prostate-specific antigen (2011) (0)
[Management of a hormone dependent cancer with endocrine therapy--prostate cancer]. (2001) (0)
Surviving cancer in Asia: cross-boundary cancer studies, University of Tokyo. (2021) (0)

This paper list is powered by the following services:

Other Resources About Hideyuki Akaza

en.wikipedia.org

What Schools Are Affiliated With Hideyuki Akaza?

Hideyuki Akaza is affiliated with the following schools:

Hideyuki Akaza's Academic­Influence.com Rankings